• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Aildenafil Citrate Tablets
Retatrutide 2381089-83-2
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen

FDA OKs Topcon’s Ocular Diagnostic Instrument

biospaceJanuary 24, 2018

Tag: FDA , Topcon

Topcon Medical Systems said today that its DRI OCT Triton Series system won 510(k) clearance from the FDA.

The company’s ocular diagnostic instrument features a built-in retinal camera, eye-tracking and a 1 micron, 1050 nm light source with a scanning speed of 100,000 A-scans/second.

Topcon’s touted its system as being able to quickly penetrate ocular tissues without being obscured by hemorrhage or media opacities.

Previous:Bio-Rad Wins Additional FDA Clearances for Blood Typing Products

Next:Study Shows Superiority of PharmaJet Needle-Free Injector for Poliovirus Vaccine Administration

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

FDA OKs Topcon’s Ocular Diagnostic Instrument | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

You may like
More>>

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0
Meclozine HCL (FDA)

Meclozine HCL (FDA)
Tobramycin base( FDA)

Tobramycin base( FDA)
Daunomycin HCL( FDA)

Daunomycin HCL( FDA)
Adriacin HCL (FDA)

Adriacin HCL (FDA)
Fluorfenicol( FDA)

Fluorfenicol( FDA)
Mitomycin ( FDA)

Mitomycin ( FDA)
lribrin Benzenesulfonate (FDA GMP)

lribrin Benzenesulfonate (FDA GMP)
Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers
9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service